Minneapolis Heart Institute Foundation® selected to test less invasive procedure for carotid artery stenosis
Minneapolis, MN - January 14, 2016 - The carotid arteries supply oxygenated blood to the brain. Every year, more than 300,000 people in the United States are diagnosed with blockages, or plaques, in their carotid artery. When these arteries become blocked due to plaque build-up, an individual is at high risk for a stroke if the plaque ruptures and flows to the brain. Many individuals can manage carotid artery disease with medications and lifestyle changes. However, many may require carotid artery revascularization surgery to repair the blockage in the artery. Carotid endarterectomy has been the gold standard of treatment with carotid stenting reserved for those who are high risk for open surgery. While largely effective in some patients, carotid stenting from the transfemoral route has been found to carry a higher risk of stroke, with a significant amount of this risk felt to be related to the approach.
The FDA recently approved a new Transcarotid Artery Revascularization (TCAR) procedure that utilizes the ENROUTE® Transcarotid Neuroprotection and Stent System from Silk Road Medical. The TCAR procedure offers patients a potentially safer method of carotid stenting through a small cut down at the base of the neck and direct carotid artery access along with neuro-protective flow reversal during delivery of the stent. The Minneapolis Heart Institute Foundation® (MHIF) was selected as the only center in the four state area to participate in the ROADSTER 2 Study. Jessica Titus, MD, and Timothy Sullivan, MD, vascular surgeons at the Minneapolis Heart Institute® at Abbott Northwestern Hospital, will serve as Principal Investigator and Co-Investigator, respectively, for the trial. "We are excited to be able to bring this carotid artery revascularization option to our patients. It combines the advantages of a minimally invasive approach for high risk patients with a lower stroke risk than the standard method for carotid stent placement." said Dr. Titus.
Read More: http://www.eurekalert.org/pub_releases/2016-01/mhif-vsr011516.php
StartUp Health last month released its annual health insights report for 2015 and if there's one overarching theme, it's that the digital health industry is maturing. What's interesting to StartUp Health co-founder and CEO Unity Stoakes is how quickly the landscape has changed over the past five years. In 2010, the digital health sector generated about $1 billion in investment. The sector is expected to bring in a total of $6 billion in funding in 2015.
REDWOOD CITY, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the publication of a manuscript in Cancer Research describing OncoMed's efforts to develop novel therapeutics against R-spondin (RSPO) targets and elucidating the link between expression of the RSPO cancer stem cell pathway and tumor growth. OncoMed is currently conducting a Phase 1a/b clinical trial of its anti-RSPO3 (OMP-131R10) antibody.
$70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved
Six-Gene Predictive Biomarker Identified for Use in Breast Cancer
The Centers for Disease Control and Prevention report 86 million American adults have prediabetes, and of those, as many as a third will become diabetics within five years.
Omada Health has revealed promising results from a study that looked at how well its digital health tools could help spur weight loss among Medicare members, a milestone for the company a couple of months after it roped in new funding to develop its health management program.
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
Preclinical Comparison Study Shows Improved Anti-Tumor and Immune Responses for Anti-DLL4/VEGF Bispecific Plus Anti-PD1 vs. Either Alone
Silk Road Medical Announces up to $57 Million in New Funding for Novel Approach to Preventing Strokes
Via: PR Newswire
Financing to Support Commercialization of First-in-Class Products for TransCarotid Artery Revascularization (TCAR) Procedure
Via: MedCity News
A few months after Outset Medical’s huge fundraise to support the clinical roll outof its Tablo dialysis system — one of the largest medtech funding rounds this year — CEO Leslie Trigg spoke at Heath 2.0 about how the company wants to transform how we think of dialysis. Aside from adding musical functions and animation and collaborating with the likes of DaVita, it wants to give patients access to their dialysis data.